Yale Neurology for Primary Care Symposium

This half-day CME program equips primary care providers with practical, evidence-based strategies to recognize, diagnose, and manage common neurological conditions. Expert Yale faculty will deliver a dynamic curriculum featuring didactic lectures, case-based presentations, and interactive discussions. Topics include peripheral neuropathy, EMG/NCS in primary care, cognitive impairment, Parkinson’s disease, tremor, and advances in migraine care, with a keynote lecture on new developments in the treatment of Alzheimer’s disease.

With a focus on closing knowledge and practice gaps, the symposium will provide clinicians with updated diagnostic methods, therapeutic options, and best practices for timely referrals—ultimately enhancing patient outcomes across the region.

1. Apply diagnostic approaches and treatment strategies for peripheral neuropathies (autoimmune and hereditary), including the role of electro diagnostic testing.
2. Evaluate recent advances in the diagnosis and treatment of neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease
3. Differentiate and manage common neurological presentations, including mild cognitive impairment, tremor, and gait imbalance.
4. Discuss emerging therapies for migraine management
5. Determine appropriate pathways for urgent and non-urgent referrals to general neurology and subspecialties, and recognize common neurologic symptoms and diagnoses encountered in daily practice.

Registration fee* for in-person attendance, includes continental breakfast, refreshment break(s), and lunch:

• Physicians - $50.00

• Allied Health Professionals/Trainees - $30.00 

*All cancellations must be received in writing (or via e-mail) at least one week prior to the start of the conference to receive a refund. Any requests for refunds received after this date, or by telephone, will not be honored.

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement
The Yale School of Medicine designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
It is the policy of Yale School of Medicine, Continuing Medical Education (CME), to ensure all accredited activities are developed free from the control of ineligible companies (those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) and are balanced, objective and scientifically rigorous. All individuals in a position to control content of an accredited CE activity (such as planners, instructors, authors, course directors, speakers, moderators, reviewers, etc.) are required to disclose all financial relationship(s) with ineligible companies that has occurred within the past 24 months. 

Mitigation of Financial Relationships Statement

Yale Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including planners, instructors, authors, course directors, speakers, moderators, reviewers or others are required to disclose all financial relationships with ineligible entities (those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients). All relevant conflicts of interest have been mitigated prior to the commencement of this activity.

Mitigation of Relevant Financial Relationships

Yale Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Sayed A Azizi, MD, PhD, MD, PhD, FANA, FAAN
Clinical Chief of Behavioral Neurology and Memory Disorders
Yale School of Medicine
New Haven, CT

Co-Director, Faculty

Nothing to disclose

Christopher H Gottschalk, MD
Chief, General Neurology
Yale School of Medicine
New Haven, CT

Co-Director, Faculty

Consulting Fee-Abbvie|Honoraria-LundBeck|Consulting Fee-Impel Neuropharma|Consulting Fee-Satsuma|Consulting Fee-Spherix Global Insights |Membership on Advisory Committees or Review Panels, Board Membership, etc.-Headache Cooperative of the Northeast|Consulting Fee-Biodelivery Sciences (Relationship has ended)|Consulting Fee-Theranica |Consulting Fee-Pfizer|Consulting Fee-Tonix Pharmaceuticals

Veronica E Santini, MD
Associate Professor, Clinical Division Chief of Movement Disorders
Yale School of Medicine
New Haven, CT

Co-Director, Faculty

Independent Contractor (included contracted research)-Scion NeuroStim Inc|Grant or research support-Ono pharmaceuticals |Grant or research support-MeiraGTx, LLC|Grant or research support-Mission MSA

Sasa Zivkovic, MD, PhD
Professor
Yale School of Medicine
New Haven, CT

Course Director, Faculty

Consulting Fee-Alnylam Pharmaceuticals|Consulting Fee-AstraZeneca|Consulting Fee-BridgeBio|Consulting Fee-Applied Therpeutics|Grant or research support-AstraZeneca

Benison Keung, MD
Associate Professor of Neurology
Yale School of Medicine
New Haven, CT

Faculty

Nothing to disclose

Amar Patel, MD
Associate Professor of Neurology
Yale School of Medicine
New Haven, CT

Faculty

Nothing to disclose

Friday, March 20, 2026

This activity is funded by Educational Grants  along with Exhibit Support from the following companies:

Grantors:

1. Argenx

2. Bristol Myers Squibb

3. Eisai

4. Grifols

5. Roche

Exhibitors

1. Alnylam

2. Amgen

3. AstraZeneca

4. CSL Behring

5. Eisai

6. Lilly

7. Lundbeck

8. Pfizer

We are grateful for their support!